ONE Retreats and Canadian Centre Collborate on Psilocybin Research
Our collaboration examines low-dose psilocybin therapy for major depressive disorder in a two-phase study. Phase 1 evaluates immediate effects in a controlled trial while Phase 2 refines dosing and assesses long-term outcomes in a retreat setting.
Novel Collaboration Bridges Academic Research with Hands-On Training in Psychedelic-Assisted Therapy
Advancing Psilocybin Therapy
At ONE Retreats, we are proud to partner with The Canadian Centre for Psychedelic Science to advance research and practice in psilocybin-assisted therapy for mental health care. This collaboration brings together rigorous scientific investigation with practical therapeutic methods to address Major Depressive Disorder in a controlled retreat setting.
Phase 1
In this initial phase, we are conducting a randomized, placebo-controlled crossover study to evaluate the safety and efficacy of low-dose psilocybin in individuals with mild to moderate depressive symptoms. The study targets subjects who meet DSM-5 criteria for Major Depressive Disorder and have either not pursued standard treatment or have experienced limited success with it. This feasibility study is designed to assess the short-term impact of microdosing on depressive symptom ratings, setting the stage for future research.
Phase 2
Building on the insights from Phase 1, Phase 2 will expand the study to a broader participant base and further integrate the retreat experience with clinical outcomes. This phase aims to refine dosing protocols and evaluate both immediate and sustained improvements in depressive symptoms, while incorporating enhanced monitoring and support measures. The data gathered will contribute to developing evidence-based guidelines for psilocybin-assisted therapy within a safe and structured retreat environment.